Parabilis Medicines to Present Updated Zolucatetide Clinical Data at ESMO
The presentation will include updated data from the ongoing Phase 1/2 trial, including a dose-optimization arm intended to inform dose and regimen selection for a Phase 3 registrational trial in desmoid tumors. The company will host a webcast on October 24, 2026, at 6 p.m. CEST / 12 p.m. EDT.